298181-83-6Relevant academic research and scientific papers
Convenient synthesis of 5,6,7,8-tetrahydroquinolin-8-ylamine and 6,7-dihydro-5H-quinolin-8-one
McEachern,Yang,Chen,Skerlj,Bridger
, p. 3497 - 3502 (2003)
A novel two-step synthesis of 5,6,7,8-tetrahydroquinolin-8-ylamine, involving regioselective nitrosation of 5,6,7,8-tetrahydroquinoline followed by oxime reduction, is described. Oxime hydrolysis affords 6,7-dihydro-5H-quinolin-8-one.
Synthetic Activators of Cell Migration Designed by Constructive Machine Learning
Bruns, Dominique,Merk, Daniel,Santhana Kumar, Karthiga,Baumgartner, Martin,Schneider, Gisbert
, p. 1303 - 1308 (2019)
Constructive machine learning aims to create examples from its learned domain which are likely to exhibit similar properties. Here, a recurrent neural network was trained with the chemical structures of known cell-migration modulators. This machine learning model was used to generate new molecules that mimic the training compounds. Two top-scoring designs were synthesized, and tested for functional activity in a phenotypic spheroid cell migration assay. These computationally generated small molecules significantly increased the migration of medulloblastoma cells. The results further corroborate the applicability of constructive machine learning to the de novo design of druglike molecules with desired properties.
CXCR2 ANTAGONIST
-
, (2020/11/23)
A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof.
Multi-substituted amine compound and its preparation and use (by machine translation)
-
Paragraph 0627; 0628; 0636; 0637, (2018/04/27)
The invention belongs to the field of medical technology, in particular, the present invention provides the following formula I shown multi-substituted amine compound or its isomer or its pharmaceutically acceptable salt, ester, prodrug or hydrate, its pharmaceutical composition, preparation method thereof and its use in the preparation of medicine for treating aids in use. The compound or pharmaceutical composition containing the compound can be used as an inhibitor for inhibiting HIV integrase with LEDGF/p75 between protein - protein interaction and HIV integrase dimerization, then can be used for the treatment of aids. . (by machine translation)
An air and moisture tolerant iminotrihydroquinoline-ruthenium(ii) catalyst for the transfer hydrogenation of ketones
Li, Jiaoyan,Ma, Yingmiao,Wang, Zheng,Liu, Qingbin,Solan, Gregory A.,Ma, Yanping,Sun, Wen-Hua
, p. 8738 - 8745 (2018/07/13)
Reaction of 8-amino-5,6,7,8-tetrahydroquinoline with RuCl2(PPh3)3 at room temperature affords the ruthenium(ii) chelate (8-NH2-C9H10N)RuCl2(PPh3)2 (E), in which the two triphenylphosphine ligands are disposed mutually cis. By contrast, when the reaction is performed at reflux ligand oxidation/dehydrogenation occurs along with cis-trans reorganization of the triphenylphosphines to form the 8-imino-5,6,7-trihydroquinoline-ruthenium(ii) complex, (8-NH-C9H9N)RuCl2(PPh3)2 (F). Complex F can also be obtained in higher yield by heating a solution of E alone to reflux. Comparison of their molecular structures highlights the superior binding properties of the bidentate imine ligand in F over its amine-containing counterpart in E. Both complexes are highly effective in the transfer hydrogenation of a wide range of alkyl-, aryl- and cycloalkyl-containing ketones affording their corresponding secondary alcohols with loadings of as low as 0.1 mol%. Significantly, F can deliver excellent conversions even in bench quality 2-propanol in reaction vessels open to the air, whereas the catalytic efficiency of E is diminished by the presence of air but only operates efficiently under inert conditions.
Auxiliary-assisted palladium-catalyzed halogenation of unactivated C(sp3)-H bonds at room temperature
Yang, Xinglin,Sun, Yonghui,Sun, Tian-Yu,Rao, Yu
, p. 6423 - 6426 (2016/05/24)
The direct transformation of unactivated C(sp3)-H bonds into C-halogen bonds was achieved by palladium catalysis at room temperature with good functional group tolerance. Some drugs and natural products were readily modified by this method. Merged with substitution reaction, newly formed C-X bonds can be transformed into diverse C-O, C-S, C-C and C-N bonds. A preliminary mechanism study demonstrates that solvent is crucial for C-H activation and the C-H activation step is involved in the rate-limiting step. An isolated Pd(ii) intermediate can be transformed into a halogenated product with the retention of conformation which suggests that concerted reductive elimination from Pd(iv) to form a C-X bond was favored.
Microwave-accelerated reductive amination between ketones and ammonium acetate
Dong, Li,Aleem, Saadat,Fink, Cynthia A.
experimental part, p. 5210 - 5212 (2010/11/05)
A new procedure for reductive amination between ketones and ammonium acetate has been developed to access a variety of primary amines. This protocol takes advantage of microwave heating to significantly accelerate the reaction and offers a convenient and effective method to access some interesting amines. This new procedure compares favorably to previously reported approaches in terms of practicality, efficiency, and functional group compatibility.
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication
Skerlj, Renato T.,Bridger, Gary J.,Kaller, Al,McEachern, Ernest J.,Crawford, Jason B.,Zhou, Yuanxi,Atsma, Bem,Langille, Jonathon,Nan, Susan,Veale, Duane,Wilson, Trevor,Harwig, Curtis,Hatse, Sigrid,Princen, Katrien,De Clercq, Erik,Schols, Dominique
body text, p. 3376 - 3388 (2010/09/05)
The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure-activity relationship (SAR) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N′-((1H-benzo[d]imidazol-2-yl)methyl)- N′-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 μM. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.
AMD070, a CXCR4 chemokine receptor antagonist: Practical large-scale laboratory synthesis
Crawford, Jason B.,Chen, Gang,Gauthier, David,Wilson, Trevor,Carpenter, Bryon,Baird, Ian R.,McEachern, Ernie,Kaller, Alan,Harwig, Curtis,Atsma, Bem,Skerlj, Renato T.,Bridger, Gary J.
, p. 823 - 830 (2013/01/03)
An efficient and convergent four-step synthetic route to the CXCR4 chemokine receptor antagonist AMD070 (1) has been developed which employs only a single chromatographic step in the entire sequence. Novel reductive amination methods have been developed for the coupling of 2 and 3 in which a dehydrative imine formation is followed by reduction with an attenuated borohydride reagent (zinc chloride and sodium borohydride). Selective extraction methods were employed to purify synthetic intermediates and remove reagents and impurities. A procedure has also been developed to isolate 1 in a pure crystalline form.
CHEMICAL COMPOUNDS
-
Page/Page column 112, (2010/10/20)
The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind specifically to the chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 and/or CCR5 of a target cell.
